Concepedia

Author

Yaming Hang

Takeda (United States)

Also Known As

Y. Hang, Yaming Hang, Zhao, Jing

27

Publications

3.3K

Citations

11

H-Index

36

Concepts

All Affiliations

Takeda (United States)Biogen (United States)Merck & Co., Inc., Rahway, NJ, USA (United States)AbbVie (United States)Cairo University
YH

About

Yaming Hang is an author at Takeda (United States) specializing in medicine, pharmacokinetics, and pharmacotherapy.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

3

3

3K

2

Engineering

1

1

17

3

Health Sciences

1

1

12

4

Natural Sciences

1

1

17

5

Biomedical Engineering

1

1

12

Yaming Hang

×

9

Publications

3.2K

Citations

9

H-Index

YearCitations

The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease

Jeff Sevigny, Ping Chiao, Thierry Bussière,

Nature

2016

3K

Pharmacokinetics and Pharmacodynamics of Once-Daily versus Twice-Daily Raltegravir in Treatment-Naïve HIV-Infected Patients

Matthew L. Rizk, Yaming Hang, Wen‐Lin Luo,

Antimicrobial Agents and Chemotherapy

2012

92

Orexin 2 receptor‐selective agonist danavorexton (<scp>TAK</scp>‐925) promotes wakefulness in non‐human primates and healthy individuals

Rebecca Evans, Haruhide Kimura, Masato Nakashima,

Journal of Sleep Research

2023

26

Oveporexton, an Oral Orexin Receptor 2–Selective Agonist, in Narcolepsy Type 1

Yves Dauvilliers, Giuseppe Plazzi, Emmanuel Mignot,

New England Journal of Medicine

2025

24

Population Pharmacokinetics of Daclizumab High-Yield Process in Healthy Volunteers and Subjects with Multiple Sclerosis: Analysis of Phase I–III Clinical Trials

Lei Diao, Yaming Hang, Ahmed A. Othman,

Clinical Pharmacokinetics

2016

19

Protein Image Alignment via Piecewise Affine Transformations

Florian A. Potra, Xing Liu, Françoise Seillier‐Moiseiwitsch,

Journal of Computational Biology

2006

17

Population PK–PD analyses of CD25 occupancy, CD56<sup>bright</sup> NK cell expansion, and regulatory T cell reduction by daclizumab HYP in subjects with multiple sclerosis

Lei Diao, Yaming Hang, Ahmed A. Othman,

British Journal of Clinical Pharmacology

2016

17

A Disease Progression Model to Quantify the Nonmotor Symptoms of Parkinson’s Disease in Participants With Leucine‐Rich Repeat Kinase 2 Mutation

Malidi Ahamadi, Nitin Mehrotra, Nathan Hanan,

Clinical Pharmacology & Therapeutics

2021

17

A mechanistic pharmacokinetic model for intrathecal administration of antisense oligonucleotides

Andreas A. Linninger, Dipak Barua, Yaming Hang,

Frontiers in Physiology

2023

12

Page 1